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Abstract
Pulmonary hypertension (PH) is a progressive vascular disease of pulmonary
arteries that impedes ejection of blood by the right ventricle. As a result there is an
increase in pulmonary vascular resistance and pulmonary arterial pressure causing
right ventricular hypertrophy (RVH) and RV failure. The pathology of PAH involves
vascular cell remodeling including pulmonary arterial endothelial cell (PAEC)
dysfunction and pulmonary arterial smooth muscle cell (PASMC) proliferation.
Current therapies are limited to reverse the vascular remodeling. Investigating a
key molecule is required for development of new therapeutic intervention.
Thymosin beta-4 (Tb4) is a ubiquitous G-actin sequestering protein with diverse
biological function and promotes wound healing and modulates inflammatory
responses. However, it remains unknown whether Tb4 has any protective role in
PH. The purpose of this study is to evaluate the whether Tb4 can be used as a
vascular-protective agent. In monocrotaline (MCT)-induced PH mouse model, we
showed that mice treated with Tb4 significantly attenuated the systolic pressure and
RVH, compared to the MCT treated mice. Our data revealed for the first time that
Tb4 selectively targets Notch3-Col 3A-CTGF gene axis in preventing MCT-induced
PH and RVH. Our study may provide pre-clinical evidence for Tb4 and may
consider as vasculo-protective agent for the treatment of PH induced RVH.
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Introduction
Thymosin b4 (Tb4), a 43-amino acid actin-binding protein encoded by gene
Tmsb4x on the X chromosome in mouse, displays abundant protective effects on
diverse pathological conditions [1–3]. This includes promoting the migration of
endothelial cells [4–7], accelerating angiogenesis [8], [9], downregulating
inflammatory response[10–12] and inhibiting apoptosis and oxidative damage
[11], [13–15]. At cardiac remodeling setting, it has been reported that treatment
with Tb4 prior to myocardial infarction improved cardiac performance,
abrogated scar formation, and enhanced cardiomyocytes survival [16–18]. These
cardio-protective effects may be the ability of Tb4 to stimulate the differentiation
of new coronary vascular cells like vascular smooth muscle cells, thereby,
improving cardiac capillary bed formation including coronary [7], [19], [20].
Together, these data indicate that stimulation with Tb4 may have positive effects
on vessel formation and may inhibit disease progression post cardiac injury. In
regards to the role of Tb4 in lung disease progression, De Santis M et al. showed
the presence of higher concentration of Tb4 in bronchoalveolar lavage fluid of
scleroderma lung disease patients [21], indicating a protective role against lung
tissue damage.
Pulmonary hypertension (PH) is a critical cardiopulmonary disorder marked
by increases in pulmonary artery pressure and pulmonary vascular resistance that
causes significant morbidity and mortality in the world [22]. PH is a vascular
disease that obstructs the pulmonary arteries. The disease is characterized by a
progressive pulmonary vasculopathy which leads to increased pulmonary arterial
pressure (PAP), right ventricular hypertrophy (RVH), fibrosis and RV failure. The
pathogenesis of PH is attributed to the collective effects of vascular remodeling
including pulmonary arterial smooth muscle cell (PASMC) proliferation, medial
hypertrophy and pulmonary arterial endothelial cell (PAEC) dysfunction resulting
in lumen obliteration [23]. Current therapies are limited and fail to fully reverse
vascular remodeling [24]. Identifying key molecule for the treatment of PH is
required for the development of new targeted therapeutics.
Previously, we have shown that monocrotaline (MCT)-induced PH-mediated
RVH was prevented by cardiac and lung specific inhibition of NF-kB [25], [26].
We identified the BMP-SMAD-Id-Notch signaling axis which contributes a
critical role in MCT-induced PH and RVH [25], [26]. Recently, Tb4 was shown to
protect mice from bleomycin-induced lung damage [27], indicating a possible
role of this G-actin sequestering peptide in lung disease. Thus, investigating the
mechanism by which Tb4 coordinates the cellular function is a key to understand
the underlying molecular mechanism of PH-induced RVH and fibrosis. The
molecular pathways including BMP-Id-Notch signaling are thought to contribute
a pivotal role in the development of MCT-induced PH in rodent model. However,
the role of Tb4 in this setting is currently unknown. This study is, therefore,
designed to test a novel concept that Tb4 may be considered for the treatment of
PH in MCT-induced mouse PH model. The rational of this study is to elucidate
how Tb4 modulates the BMP-Id-Notch signaling pathways in the event of PH.
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Material and Methods
Twelve-week-old male mice (,25 g) were used for experiments. The studies were
conducted with the approval of Institutional Animal Care and Use Committee at
the Texas A&M Health Science Center and Scott &White Hospital.
Induction of pulmonary hypertension (PH)
The MCT-induced PH mouse model was developed as described previously [24].
Briefly, wild-type (WT) mice received an intraperitoneal (i.p) injection of MCT
(80 mg/kg body wt) every 20 days for 3 times. Age- and sex-matched WT with
normal saline-injected mice of C57BL/6 background served as controls. A total of
six mice were studied in each group. For Tb4 treatment, animals received an i.p
injection of Tb4 (200 mg/200 ml PBS) prior to MCT treatment. The control group
received 200 ml PBS. The i.p. injection was given every day for 3 days following
MCT for a week and then twice a week until the mice were euthanized. The tissues
were collected for experimental use. All mice were fed standard rodent chow and
provided water ad libitum.
Determination of RV pressure and RVH
The RV pressure was determined using iWorks System, pressure catheter (CATH-
SCI-1200) as described previously [24]. Briefly, mice were anesthetized with 3.5%
isoflurane and subsequently maintained on 1.5% isoflurane during the procedure
to maintain the heart rate about 450 beats per minute. The catheter was inserted
into the right jugular vein and was advanced into the RV and pulmonary artery.
The RV pressure and hemodynamic measurements were recorded using iWorks
Software (iWorx IX/228S Data Acquisition System with the Scisense Advantage
pV control unit version 5.0). All mice were euthanized after the procedure. The
hearts and lungs were excised, flushed with cold PBS to remove blood. Hearts
were then weighed and RV portions were carefully removed and RVH was
determined as described [25], [26]. The samples were then frozen in liquid
nitrogen and stored at 280 C˚ for isolation of RNA and proteins or stored in 10%
buffered formalin for morphological examination or histological staining.
Morphological examination
Lungs and RVs were fixed in 10% phosphate-buffered formalin, stained with
hematoxylin and eosin (H&E) and Masson’s trichrome, respectively; photo-
graphed using a DP-72 color camera.as described previously [25], [26]. The
sections were examined by bright-field microscopy using an Olympus microscope
(Olympus, Tokyo, Japan) and photographed using a DP-72 color camera.
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RNA extraction and quantitative real-time polymerase chain
reaction (q RT-PCR)
RNA was extracted from the lung and RV tissue of WT, Tb4, WT+MCT and
MCT+ Tb4 mice using an RNEasy kit (Qiagen, Valencia, CA, USA), following the
manufacturer’s instructions. The qRT-PCR was performed using gene-specific
primers as described previously [25], [26].
Western blot analysis
The lung and RV heart tissue were pulverized in liquid nitrogen and the total
proteins were extracted using tissue extraction reagents (T-PER, Pierce, Rockford,
IL). For in vitro analysis, the cells were lysed with RIPA lysis Buffer (Santa Cruz
Biotechnologies, Santa Cruz, USA). The Western blotting and the subsequent
quantification of each blot were performed as described previously [25], [26]. The
primary antibodies for BMPR2, Notch3 and Id1 were from Santa Cruz
Biotechnologies (Santa Cruz, CA). Collagen type III A (Col 3a) antibody was
purchased from Rockland Immunochemicals (Gilbertsville, PA, USA) and
antibodies for CTGF and GAPDH were from Cell Signaling Technologies,
Danvers, MA, USA).
Culture of Lung Microvascular Endothelial Cells (MVEC)
Lung MVECs were purchased from VEC Technologies (Rensselaer, NY, USA).
Cells were cultured and passaged in MCDB-131 complete medium (VEC
Technology, NY). Lung MVECs were serum-free for 24 h before stimulation with
TGF-b1 and MCT (25 mmol), separately. No cellular toxicity was observed at
25 mmol of MCT in lung MVEC.
Culture of Lung fibroblasts
Lung fibroblasts were prepared from WT mice lungs using collagen dispersion
method as described previously [13]. Lung fibroblasts were serum-free for 24 h
before stimulation with Ang II.
Statistical analysis
All experiments were performed at least three times for each determination. Data
are expressed as the means ¡ SE and were analyzed using one-way ANOVA and
secondary analysis for significance with Newman-Keuls Multiple comparison test,
using Prism 5.0 GraphPad software (GraphPad, San Diego, CA). P,0.05 was
considered statistically significant.
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Results
Effect of Tb4 on RV pressure and RVH
The pathogenesis of MCT-induced PH was evaluated through RV pressure
measurement. There was a significant increase in the RV pressure in the MCT-
treated WT mice, compared with the untreated WT mice (37.51¡1.843 vs.
27.53¡1.062 mm Hg, p,0.05). Treatment with Tb4 showed significant reduction
in RV pressure (27.81¡0.89vs. 37.51¡1.843 mm Hg, p,0.05) in WT+MCT
group, compared with the MCT-treated WT mice (Fig. 1A).
RVH was determined by a ratio of right ventricle (RV) weight to left ventricle
(LV) plus inter ventricular septum (S) weight [RV/(LV+S)]. There was a
significant increase in the RV/(LV+S) ratio in the MCT-treated WT mice
(0.25¡0.029, p,0.05), compared with the untreated WT (0.21¡0.013) mice.
Treatment with Tb4 showed significant attenuation of RV/(LV+S) ratio
(0.23¡0.021) in the WT+MCT group, compared with the MCT-treated WT mice
(p,0.05) (Fig. 1B).
To further evaluate the hypertrophic response induced by MCT in the RV, we
determined myocyte cross-sectional area by wheat germ agglutinin (WGA)
staining and analyzed hypertrophic marker genes. The representative images and
averaged bar graphs from the WGA staining of hearts from WT, WT+MCT and
MCT+ Tb4 groups are shown in Fig. 1C. WGA staining showed a 1.72-fold (WT:
0.3719¡0.017 vs. MCT: 0.6430¡0.026, p,0.01) increase in cardiomyocytes
cross-sectional area in the MCT-treated WT mice (Fig 1D). The MCT-induced
right ventricular cardiomyocytes hypertrophy was significantly alleviated in
MCT+ Tb4 mice (MCT: 0.6430¡0.026 vs. MCT+ Tb4: 0.4372¡0.020, p,0.01)
(Fig. 1D).
Gene expression of ANF and b-MHC was increased to 3.8266¡0.157-fold and
3.0833¡0.262-fold (p,0.01) respectively, in MCT-treated WT mice, compared
with the untreated WT mice. Significant reduction of ANF and b-MHC genes was
observed in MCT+ Tb4 mice (1.247¡0.112-fold and 1.292¡0.080-fold, p,0.05,
respectively), compared with MCT-treated group (Fig. 1E). There were no
significant changes observed in Tb4-treated mice.
Effect of Tb4 on MCT-Induced Lung and RV Injury
The histological alterations in lung and RV damages are demonstrated in Fig. 2.
The upper panel of Fig. 2A demonstrated the H&E staining of RV section and the
lower panel showed Masson’s trichrome staining of WT, WT+MCT and MCT+
Tb4 groups. Our data showed enhanced fibrosis in the RV section
(0.38¡0.002vs.26.75¡2.348), compared to WT mice. The level of fibrosis was
significantly reduced in MCT+ Tb4 group (2.831¡0.197) when compared with
WT+MCT counterpart. MCT injection triggered intense infiltration of macro-
phages in the lungs of WT mice treated with MCT (Fig. 2B, upper panel) and the
normal structure of alveoli was lost in many areas. Treatment with Tb4
significantly reduced these maladaptive changes in the MCT-treated WT mice
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(Fig. 2B, upper panel). Masson’s trichrome staining showed increased collagen
deposition (8.75¡2.21 vs. 67.75¡3.30) in the pulmonary interstitium in the
MCT-treated WT mice, compared to untreated WT mice (Fig. 2B, lower panel).
The MCT-induced lung interstitial fibrosis was significantly alleviated in the
MCT+ Tb4 mice (36.0¡2.16), compared to WT+MCT mice (Fig. 2B). The
quantification of tissue fibrotic areas of lungs and RV were shown in Fig. 2C.
Figure 1. Tb4 treatment reduced the right ventricle pressure and RVH induced by MCT treatment. (A)
Representative of RV pressure measurement using iWorks pressure catheter showing the RV pressure in the
WT, WT+MCTand MCT+ Tb4 groups. Data are expressed as means¡ SE from at least 3 independent mice.
(B) The RV/LV+SP ratio (index for RVH) of the above group of mice. Data are expressed as means¡ SE from
at least 3 independent mice. (C) Representative images and averaged bar graphs of WGA staining for RV
transverse section of WT, WT+MCT, and Tb4+MCT mice. (D) The mRNA expression of ANF and b-MHC was
determined by quantitative RT-PCR in WT, Tb4, and WT +MCT, and MCT+ Tb4 mice. *p,0.05 compared with
the WT mice, **p,0.01 compared with the WT mice for ANF and b-MHC gene expression analysis and
#p,0.05 compared with the WT+MCT mice.
doi:10.1371/journal.pone.0110598.g001
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Tb4 treatment alters the expression and level of Notch3 and
ICAM1 but not BMPR2 and Id1 in the lungs
To determine the protective effect of Tb4 in the MCT-treated PAH mouse model,
we evaluated the gene expression and protein level of BMPR2, Notch3 and ICAM1
in the lung tissue of WT, Tb4, WT+MCT and MCT+ Tb4 groups by real-time
PCR and Western blot analysis. Real-time PCR analysis showed that MCT
treatment increased Notch3 (2.847¡0.5921, p,0.05) and ICAM1 (4.18¡0.7742,
p,0.05) mRNA expression; and attenuated Id1 (0.5972¡0.06799, p,0.05) and
BMPR2 (0.4686¡0.1196, p,0.05) mRNA expression. The Tb4 treatment showed
significant reduction in Notch3 (1.34¡0.2378, p,0.05) and ICAM1
(3.239¡0.663) mRNA expression stimulated by MCT. We did not observe any
changes or restoration of Id1 and BMPR2 expression (Fig. 3A). Western blot
Figure 2. MCT-induced lung and RV injury in WT and Tb4 treated mice. A. Representative images of RV
section showing H& E staining (upper panel). The lower panel is showing Masson’s trichrome staining. B.
Representative of H&E staining images showing the MCT-induced lung injury in WT and Tb4-treated mice
(upper panel). The lower panel represents Masson’s trichrome staining showing the MCT-induced collagen
deposition in WT and Tb4-treated mice. C. The graphs show the quantification of Fig A and B (lower panels)
by densitometry. Data are expressed as means ¡ SE from 5 independent mice. For lung quantification,
*p,0.01 compared to WT mice and # p,0.01 compared to WT+MCT group. For RV quantification, *p,0.05
compared to WT mice and #p,0.05 compared to WT+MCT mice. **p,0.01 compared to WT vs. MCT+ Tb4
mice.
doi:10.1371/journal.pone.0110598.g002
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analysis showed that MCT treatment increased Notch3 (2.179¡0.2614,p,0.05)
and ICAM1 (2.272¡0.3952, p,0.05) levels and decreased the Id1
(0.648¡0.0703,p,0.05) and BMPR2 (0.5986¡0.0646,p,0.05) levels in the
mouse lung tissue (Fig. 3B and 3C). The Tb4 treatment showed reduction only in
Notch3 (1.488¡0.1086,p,0.05) protein level stimulated by MCT. However, there
was a slight reduction in the ICAM1 level.
Tb4 treatment significantly reduces Col 3a and CTGF gene
expression and protein level in the lungs
In order to determine whether Tb4 has any influence on fibrosis, we evaluated the
changes of Col 3a and CTGF in the lung tissues of WT, Tb4, WT+MCT and
MCT+Tb4 groups by real-time PCR and Western blot analysis. WT mice treated
with MCT showed significant up-regulation of CTGF (2.889¡0.112, p,0.05) and
Col 3a (1.812¡0.165, p,0.05) mRNA in the mouse lung tissue. The mice treated
with Tb4 showed significant reduction in both CTGF (1.197¡0.322, p,0.05) and
Col 3a (1.238¡0.206, p,0.05) mRNA expression (Fig. 4A). Western blot analysis
showed that MCT treatment increased the CTGF (1.885¡0.328, p,0.05) and Col
3a (1.656¡0.058, p,0.05) protein level and Tb4 treatment significantly
attenuated CTGF (1.28¡0.025, p,0.05) and Col 3a (1.286¡0.132, p,0.05) level
(Fig. 4B and 4C).
Tb4 treatment significantly inhibits the expression and level of
Notch3 but not Id1 in the RV
The pathology of PH triggers the development of RVH and, we then determine
the efficacy of Tb4 on RVH in MCT-treated WT mouse. We further examined the
expression of Notch3 and Id1 expression in the right ventricle of WT, Tb4,
WT+MCT and MCT+ Tb4 groups by real-time PCR and Western blot analysis.
Real-time PCR analysis showed a significant increment of Notch3 mRNA
(3.631¡0.613, p,0.05) and reduction in Id1 (0.731¡0.076, p,0.05) and
BMPR2 (0.6482¡0.031, p,0.05) mRNA expression in right ventricles of MCT-
treated WT mice. The Tb4 treatment showed significant reduction in the Notch3
(2.603¡0.445,p,0.05) mRNA only (Fig. 5A).Western blot analysis showed that
MCT treatment up-regulated the Notch3 (1.765¡0.189, p,0.05) level and down-
regulated the Id1 protein level (0.676¡0.013, p,0.05), compared to the MCT-
treated mice. Importantly, the Tb4 treated group showed significant reduction in
Notch3 (1.276¡0.606, p,0.05) protein level (Fig. 5B and 5C). We did not
observe any significant changes in Id1 level in Tb4-treated group.
Tb4 treatment significantly reduces Col 3a and CTGF expression
and level in the RV
In order to examine whether MCT-induced fibrosis is attenuated in the RV, we
evaluated expression of CTGF and Col 3a in the WT, WT+MCT and MCT+ Tb4
groups by real-time PCR and Western blot analysis. Real-time PCR analysis
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showed that MCT treatment increased CTGF (6.387¡2.091, p,0.05) and Col 3a
(3.146¡0.516, p,0.05) mRNA expression in the mouse right ventricle. The Tb4
treatment reduced the CTGF (2.11¡0.639, p,0.05) and Col 3a (1.386¡0.054,
p,0.05) mRNA expression by MCT in the mouse right ventricle
(Fig. 6A).Western blot analysis showed that MCT treatment increased CTGF
(1.659¡0.145, p,0.05) and Col 3a (1.428¡0.081, p,0.05) protein levels in the
mouse right ventricle. The Tb4 treatment reduced the CTGF (1.24¡0.119,
p,0.05) and Col 3a (1.194¡0.045, p,0.05) protein levels by MCT in the mouse
right ventricle (Fig. 6B and 6C).
Tb4 treatment reduces TGFb1 and MCT-induced Notch3, ICAM1
expression in lung microvascular endothelial cells (MVEC)
To corroborate the in vivo studies, we performed our analysis using lung
microvascular endothelial cells (MVEC) stimulated with TGFb1. The TGFb1 is a
potent stimulus used in EC remodeling. To examine the efficacy of Tb4 in
vascular cell remodeling, we pretreated the cells with Tb4 followed by the
stimulation with TGFb1. Our data showed that TGFb1 significantly upregulated
Figure 3. Effect of Tb4 on MCT-induced changes of Notch3, ICAM1, Id1 and BMPR2 in mouse lung tissue. (A) Graph shows the mRNA expression of
Notch3, ICAM1, Id1 and BMPR2 in WT, Tb4, WT+MCTand MCT+ Tb4 groups. The RT-PCR was performed using their specific probes. (B) Representative
Western blots showing protein expression of Notch3, ICAM1, Id1 and BMPR2 in the above group of mice. GAPDH was used as an internal loading control.
(C) Graph shows the relative fold change in the protein expression of Notch3, ICAM1, Id1 and BMPR2. Data are expressed as means ¡ SE from 5
independent mice.*p,0.05, compared with the WT mice. #p,0.05 compared with the WT-MCT mice.
doi:10.1371/journal.pone.0110598.g003
Figure 4. Effect of the Tb4 treatment on CTGF and Col 3a expression in mouse lung tissue. (A) Graph shows the mRNA expression of CTGF and Col
3a in WT, Tb4, WT+MCTand MCT+ Tb4 groups. The RT-PCR was performed using their specific probes. (B) Representative Western blots showing protein
expression of CTGF and Col 3a in WT, Tb4, WT+MCTand MCT+ Tb4 group. GAPDH was used as an internal loading control. (C) Graph shows the relative
fold change in the protein expression of CTGF and Col 3a by densitometry. Data are expressed as means ¡ SE from 5 independent mice.*p,0.05,
compared with the WT mice. #p,0.05 compared with the WT+MCT mice.
doi:10.1371/journal.pone.0110598.g004
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the Notch3 and ICAM1 (2.937¡0.3546 and 3.50¡0.6502, p,0.05, respectively)
mRNA expression; and downregulated Id1 (0.37¡0.03464) expression, compared
to the unstimulated lung MVEC (Fig. 7A). The lung MVEC treated with Tb4
showed significant attenuation of both Notch3 and ICAM1 (1.5466¡0.2874 and
1.8566¡0.3013, p,0.05, respectively); and partially restored the Id1 expression
(0.735¡0.1150, p,0.05). In separate experiments, we determined the expression
of Notch3 and ICAM1 in MCT-stimulated lung MVEC. Our data showed that
MCT treatment significantly upregulated both Notch3 and ICAM1
(3.493¡0.4687 and 5.957¡0.6705, p,0.05, respectively) mRNA expression,
compared to the unstimulated lung MVEC (Fig. 7B). The lung MVEC treated
with Tb4 showed significant attenuation of both Notch3 and ICAM1
(1.3046¡0.2633 and 2.1166¡0.2417, p,0.05, respectively). It is also noted that
lung MVEC treated with Tb4 did not show any significant alteration of these
genes.
Figure 5. Effect of Tb4 on Id1 and Notch3 expression in the mouse right ventricle. (A) Graph shows the mRNA expression of Id1 and Notch3 in the right
ventricles of WT, Tb4 WT+MCTand MCT+ Tb4 groups. The RT-PCR was performed using their specific probes. (B) Representative Western blots showing
protein expression of Id1and Notch3 in the above group of mice. GAPDH was used as an internal loading control. (C) Graph shows the relative fold change
in the protein expression of Id1 and Notch3 by densitometry. Data are expressed as means¡ SE from 5 independent mice.*P,0.05, compared with the WT
mice. #p,0.05 compared with the WT+MCT mice.
doi:10.1371/journal.pone.0110598.g005
Figure 6. Effect of the Tb4 treatment on CTGF and Col 3a level in the right ventricle. (A) Graph shows the mRNA expression of CTGF and Col 3a in the
right ventricles of WT, Tb4, WT+ MCT and MCT+ Tb4 groups. The RT-PCR was performed using their specific probes. (B) Representative Western blots
showing protein expression of CTGF and Col 3a in the above group of mice. GAPDH was used as an internal loading control. (C) Graph shows the relative
fold change in the protein expression of CTGF and Col 3a by densitometry. Data are expressed as means ¡ SE from 5 independent mice.*p,0.05,
compared with the WT mice. #p,0.05 compared with the WT-MCT mice.
doi:10.1371/journal.pone.0110598.g006
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Tb4 treatment attenuates Ang II-induced Col 3a and CTGF
expressions in lung fibroblasts
In order to determine the efficacy of Tb4 treatment in fibrosis, we examined the
expression and level of CTGF and Col 3a in lung fibroblasts stimulated with
angiotensin II (Ang II). We used Ang II as a stimulus as it is well-accepted
stimulus for pro-fibrotic cascade as shown us previously [13] The real-time PCR
analysis showed that Ang II treatment increased CTGF (1.777¡0.286, p,0.05)
and Col 3a (2.099¡0.168, p,0.05) mRNA expression in lung fibroblasts. Lung
fibroblasts treated with Tb4 showed significant attenuation of CTGF
(1.132¡0.115, p,0.05) and Col 3a (1.303¡0.142, p,0.05) mRNA expressions,
compared to Ang II stimulation (Fig. 8A). Western blot analyses showed
significant enhancement of CTGF (1.721¡0.145, p,0.05) and Col 3a
(1.461¡0.081, p,0.05) protein level in Ang II-stimulated lung fibroblasts. Lung
fibroblasts prior treated with Tb4 showed reduction in CTGF (1.304¡0.119,
p,0.05) and Col 3a (1.181¡0.045, p,0.05) protein level, compared to Ang II
stimulation (Fig. 8B and 8C). Lung fibroblasts treated with Tb4 only did not show
any significant alteration of Col 3a and CTGF genes (data not shown).
Figure 7. Effect of Tb4 on Id1, Notch3 and ICAM1 expression in the lung MVEC. Lung MVEC was
stimulated with TGFb1 in the presence or absence of Tb4. (A) The mRNA expression of Id1, Notch3 and
ICAM1 were determined by qRT-PCR using their specific probes. The data presented are mean ¡ SE.
*p,0.05 vs. control, #p,0.05 vs. TGFb1 treatment (n53). (B) Lung MVEC was stimulated with MCT in the
presence or absence of Tb4. The mRNA expression of ICAM1 and Notch3 were measured by qRT-PCR using
their specific probes. The data presented are mean¡ SE. *p,0.05 vs. control, #p,0.05 vs. MCT treatment
(n53).
doi:10.1371/journal.pone.0110598.g007
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Discussion
Our study demonstrates for the first time that Tb4 may provide a protective role
in MCT- induced PH and RVH mouse model. Our results indicate that Tb4
selectively modulates the Notch3, Col 3a and CTGF genes and protects mice from
the lung and heart damage induced by MCT administration. Moreover, by
evaluating pertinent inflammatory markers, we provide evidence of significant
attenuation of a signature of pro-inflammatory molecules in MCT-induced PH.
We provide the following assertion by which Tb4 offers protection in MCT-
induced PH and RVH.
We showed that MCT treatment triggered the progression of PH as evidenced
by increased RV pressure in WT mice and were associated with the development
of RVH. Treatment of Tb4 was able to attenuate the RV pressure and RVH
indicated a possible protective effect in PH and RVH. The development of RVH in
WT+ MCT mice was evidenced by an increase in cardiomyocytes cross-sectional
area. The morphological changes were associated with alteration of BMPR2-Id-
Notch-3 axis genes and upregulation of hypertrophic marker genes like ANF and
b-MHC. WT+MCT mice treated with Tb4 showed significant reduction in
cardiomyocytes cross-sectional area, restoration of BMPR2-Id-Notch-3-axis genes
and reduction of hypertrophy marker genes, indicating a great potential of
therapeutic use in PH-induced RVH. Our data revealed inflammatory molecules
which were triggered by MCT treatment were significantly reduced. Besides the
anti-inflammatory effect, we demonstrated that Tb4 was further conferred the
restoration of lung damage initiated by MCT. This finding accorded with our
previous finding in myocardial ischemia model [18]. Here, we showed that
intraperitoneally administered Tb4 substantially reduced alveolar damage,
inflammatory cellular infiltrates, and interstitial edema and, alveolar exudates in
MCT-treated mice. Tb4 exerts protective effect against MCT-induced lung injury
(or toxicity) possibly via scavenging mechanism. It is likely that MCT triggered
the activation of inflammatory circuit and fibrotic effects by reactive oxygen
species (ROS) generation [28]. It is reported that MCT increased pulmonary
vascular permeability along with enhanced vasoconstrictor responsiveness in the
lungs and alveolar capillary membrane permeability, inflammation and EC injury
[29–31]. Our current study did not assess any ROS activity or anti-oxidative
enzymes pattern in the course of PH development. However, it is more likely that
Tb4 acts as a ROS scavenger and may target the anti-oxidative enzymes which, is
corroborated with our previous report [13]. Therefore, a future study on this
aspect is warranted. Furthermore, our data provide a new observation of presence
of significant fibrotic areas in the lungs of MCT-treated mice and were reduced in
Tb4-treated mice. The observation supports our previous report [18] along with
the others findings in the setting of fibrotic event [27]. Together, our data
underscore that treatment of Tb4 reduces the lung damage, attenuates
inflammatory responses and eventually restores the RV pressure.
In the line of target molecule analysis, our data indicated that Notch3-Col 3a-
CTGF genes appear to be the prime target by Tb4 in MCT-induced PH and RVH.
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Previously, we showed that BMPR2-Id-Notch3- axis genes played a critical role in
MCT-induced PAH and RVH [25], [26]. In the current study, we observed that
Tb4 preferentially targeted Notch3; however, a slight restoration of BMPR2 was
observed, but, not the Id molecules. Additionally, our data revealed more
significant reduction of fibrotic genes like Col 3a and CTGF, the hallmark for
fibrosis. The Notch system is highly conservative in evolution and plays an
important role in cell proliferation, differentiation, and apoptosis [32–34]. Earlier
report suggested that Notch3 was upregulated in PH patients and in hypoxia- or
MCT-induced rodent model of PH and, mice with homozygous deletion of
Notch3 did not develop pulmonary hypertension in response to hypoxic
stimulation [35]. Our results supported this observation and suggested an
important role of Notch signaling pathway in vascular remodeling in PH.
However, it is of note that Notch signaling is complicated and we are still unaware
of this pathway function in PH by different members of Notch; specifically,
Notch1 and 4, as they are modulated differently depending on time, environment,
and cell types. Therefore, further investigation is warranted to decipher the
specific function of each Notch members in PH.
Figure 8. Tb4 treatment attenuates CTGF and Col 3a in the lung fibroblast. Lung fibroblasts were
stimulated with Ang II in the presence or absence of Tb4. (A) The mRNA expression of CTGF and Col 3a were
determined by qRT-PCR using their specific probes. (B) The protein level of CTGF and Col 3a were
determined by Western blot using CTGF and Col 3a specific antibodies. (C) The quantification of Western blot
is shown graphically. The data presented are mean¡ SE. *p,0.05 vs. control, #p,0.05 vs. Ang II treatment
(n53).
doi:10.1371/journal.pone.0110598.g008
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Our data further advocate a potential role of Tb4 in fibrosis. We observed that
there was an increase in the expression of pro-fibrotic genes like Col 3a and CTGF
in MCT- induced PAH and RVH. Decreased expression of fibrotic genes is
beneficial because it prevents fibrosis by reducing the extracellular matrix (ECM)
deposition. Histological and molecular analysis revealed that significant ECM
deposition (collagens) in the lung and RV sections was abrogated by Tb4
treatment. This is the first report where we showed an anti-fibrotic property of
Tb4 in PH model. At molecular level, it remains unknown the underlying
mechanism of anti-fibrotic nature of Tb4 in PH model. However, it is reasonable
to assume that Tb4 may modulate the PI3K/Akt signaling to prevent fibrotic
events as reported in liver fibrosis model [36], [37]. Another possibility is that Tb4
may offer this protection through its anti-fibrotic tetra-peptide Ac-SDKP which is
the first four amino-acid [38], [39]. It has been shown in rat renal dysfunction
and fibrosis model that Ac-SDKP inhibits phosphorylation of smad2 followed by
attenuation of fibronectin, interstitial collagen, and TGF-b1 level in the nephritic
kidney [40]. Based on these reports, we may speculate that Tb4 may modulate
TGFb signaling cascade in order to reduce fibrotic events. Future studies are
currently underway to unfold the underlying molecular mechanism.
We also provide evidence that MCT-induced PH that leads to the development
of RVH; was significantly attenuated by Tb4. The morphological changes, gene
expression patterns (Notch3-Col 3a-CTGF) and RV mass were significantly
reduced by Tb4 treatment.
Finally, to evaluate the effect of Tb4 in cell culture setting (an in vitro analysis),
we confirmed our data in TGFb1-stimulated lung MVEC and Ang II-stimulated
lung fibroblast cells, separately. We observed an upregulation of both Notch3 and
ICAM1 and downregulation of Id1 in TGFb1-stimulated lung MVEC and were
significantly reduced in Tb4 treatment except moderately restoration of Id1. In
case of fibrotic process, our data further confirmed that Ang II-stimulated
upregulation of both Col 3a and CTGF (the hallmark and markers for fibrosis)
mRNA and proteins were significantly reduced in prior Tb4 treatment in the lung
fibroblasts. Together, our in vitro data suggest that upregulation of Notch3 may
initiate the dysfunction of EC in the lungs which allows the penetration of
infiltrating molecules at the site. These infiltrating molecules invade the barrier of
neighboring cells like smooth muscle cells and activate the resident of adventitious
fibroblasts. The activation of fibroblasts promotes the synthesis of ECM proteins
and induces the fibrotic response.
In conclusion, our study demonstrates for the first time that Tb4 protects the
lung injury caused by MCT injection in mouse model. In parallel, our data
provide evidence that Tb4 may be considered as a new candidate for the treatment
of PH and RVH. Recently, a randomized placebo controlled study was done in
healthy volunteers to examine the dose and toxicity effect. The data showed no
apparent toxicity effect, was well tolerated and is being considered to be used for
acute myocardial infarction [41]. It is of note that Tb4 has been considered for
phase II clinical trial for acute myocardial infarction and stroke by RegeneRx
pharmaceutical (http://www.regenerx.com). In light of this and our new insight of
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Tb4’s beneficial role in lung injury and fibrosis; our findings may offer therapeutic
opportunity to treat PAH.
Therapeutic implication
Our findings may provide a new therapeutic intervention for PH where
pulmonary vascular remodeling occurs and are relevant in the clinical settings.
Future studies are, therefore, warranted to examine the effect of Tb4 under
different experimentally induced PH models. We believe that Tb4 is a possible
therapeutic target as it has the ability to attenuate the expression of the critical
genes in PH, like Notch3, collagen I and CTGF, thereby, alleviating the damage to
the pulmonary bed in MCT-induced PH and RVH. These possibilities regarding
the mechanisms whereby Tb4 modulates the above molecules need to be further
tested experimentally in future studies.
Limitation of the Study
In this study, we evaluated the efficacy of Tb4 in MCT induced PAH and RVH.
However, the possibility of interaction between these genes and other molecular
pathways cannot be ignored. Also other PH model like hypoxia or pulmonary
artery banding in rodents needs to be further investigated under Tb4 treatment.
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